CSL commits USD1.5b to expand US operations
Make us a preferred source
Make us a preferred source on Google
The news: Biopharma giant CSL announced plans to invest USD1.5 billion ($2.31 billion) to expand its US operations over the next five years.
The context: The Australian firm said that it will funnel the spending toward manufacturing plasma-derived therapies in efforts to expand its footprint and secure the local supply chain.
Plasma-derived therapies represent the core of CSL Behring’s portfolio and the division contributed to over 70% of the group’s total revenue in fiscal year 2025.
“The US is the world’s leading source for plasma, the main component of plasma derived therapies,” said Paul McKenzie, CEO and managing director, CSL. “These important medicines are often the most effective or only therapies available for many rare or serious diseases. By expanding our onshore production capacity in the US, we are deepening our commitment to patient care, creating high-quality jobs and driving innovation in the US”
The planned investment is subject to approval by CSL’s Board of Directors.
The numbers: Since 2018, CSL said has invested over USD3 billion into its US operations, creating more than 6,500 new American jobs and bringing its total US. headcount to nearly 19,000, representing about 65% of CSL’s workforce.
